The injection process is expected to take ... s development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final ...

The cash injection comes as Biogen has been hit hard by the stalled rollout of its Alzheimer's disease drug Aduhelm (aducanumab), with Stat reporting earlier this month that the company is ...

Biogen's new management is diversifying its product portfolio and optimizing costs, but faces significant risks from market share loss and generic competition. The fair valuation of Biogen shares ...

A higher dose of Spinraza may be more effective than the currently approved dosing schedule for maintaining motor function in ...

February 28, 2025 EU regulator reiterates positive recommendation for Eisai-Biogen's Alzheimer's drug The European Union's medicines regulator on Friday reiterated its positive recommendation for ...

Biogen Inc.’s stock BIIB tumbled 7% Wednesday, after the biotech beat fourth-quarter earnings estimates but offered guidance that lagged behind consensus, as sales of its multiple sclerosis drug ...

Since 2016, the FDA has approved three disease-modifying treatments for spinal muscular atrophy, with several ...

Cambridge-based biotechnology company Biogen Inc. announced Monday that it will move its global headquarters to a new building in Kendall Square in 2028, consolidating its various branches and ...

Eisai (ESAIY) and Biogen (BIIB) announced that the Committee for Medicinal Products for Human Use, CHMP, of the European Medicines Agency, EMA, has reaffirmed its positive opinion by consensus for ...